The science behind the high-fat low-carb ketogenic diet has been around for years. It is a special diet originally developed at Johns Hopkins Hospital in the 1920s as a cure for childhood epilepsy. A diet that is still used today, some children can become seizure free or nearly seizure free on the ketogenic diet, where drugs often fail.
In recent times, studies have been done on cancer patients using the ketogenic diet, using the theory that refined carbohydrates feed cancer cells, whereas a diet induced state of ketosis can starve cancer cells. One of the most widely used dietary oils in the ketogenic diet to induce ketosis is coconut oil.
But a diet approach to curing cancer is a direct threat to the multi-billion dollar cancer industry, which depends on no cures for future growth for its cancer products, which can only be pharmaceutical drugs approved by the FDA. (See: The Cancer Industry is Too Prosperous to Allow a Cure). So for cancer patients who want to try alternative methods to treat their cancer, they must endure ridicule, fear, and scorn by doctors in mainstream medicine.
In the story below, one young man did just that. In the face of opposition from mainstream medicine, he rejected chemotherapy for his brain tumor, and was only given a couple of months to live. He chose to implement the ketogenic diet instead, and now 2 years later he is still alive and doing well, having bypassed the dangerous side effects of chemotherapy which would have, at best, probably only extended his life a couple of months.
Pablo, 27, says his survival after terminal diagnosis is down to special diet
Pablo Kelly was given months to live after doctors found a terminal tumour in his brain.
He rejected chemotherapy in favour of a specialist, meat and fat-heavy diet and is still alive two years later.
At 25 years old Pablo, from Wrangaton, was diagnosed with stage 4 glioblastoma multiforme – a terminal brain tumour. Due to the tumour’s position in Pablo’s brain it was also inoperable.
“I was devastated,” Pablo said.
“I hadn’t slept in weeks just waiting for the results. I was quite calm that morning, I knew the news wasn’t going to be good.
When doctors offered Pablo radiotherapy and chemotherapy, he decided he didn’t like the idea of a diminished quality of life and opted for a treatment that is not recommended by the NHS – a high fat, low carb food plan known as the ketogenic diet.
“The doctors said the only option they could give me was chemotherapy,” Pablo said.
“The survival statistics for people my age were about three per cent and that’s for a maximum of 15 months with chemotherapy, without it, based on my health and age, they gave me six to nine months.”
The ketogenic diet relies on measuring ketones – an acid remaining when the body burns its own fat. The theory is that by reducing the intake of carbohydrates it is possible to starve a tumour of fuel and therefore stabilise it.
“Doctors told me the ketogenic wouldn’t help me in any way,” Pablo said, “I’ve had five stable scans since January 2015 on this diet.”
We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.
The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.
The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.
John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.